CN106309363A - Paroxetine hydrochloride oral suspension and preparation method thereof - Google Patents
Paroxetine hydrochloride oral suspension and preparation method thereof Download PDFInfo
- Publication number
- CN106309363A CN106309363A CN201610845382.7A CN201610845382A CN106309363A CN 106309363 A CN106309363 A CN 106309363A CN 201610845382 A CN201610845382 A CN 201610845382A CN 106309363 A CN106309363 A CN 106309363A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- paroxetine hydrochloride
- oral administration
- mixed suspension
- administration mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses paroxetine hydrochloride oral suspension and a preparation method thereof. The paroxetine hydrochloride oral suspension is prepared from auxiliary ingredients of paroxetine hydrochloride, a stabilizing agent, a diluent, a dispersant, a wetting agent, a pH conditioning agent, a preservative, a flavoring agent, a coloring agent, a defoaming agent and the like. A colloid mill grinding process is used. The prepared paroxetine hydrochloride oral suspension has the advantages of high stability, fast absorption, fast effect taking, good mouthfeel, high bioavailability and the like.
Description
Technical field
The present invention relates to a kind of oral administration mixed suspension, particularly to a kind of paroxetine hydrochloride oral administration mixed suspension and preparation side thereof
Method.
Background technology
Depression is with hypothymergasia, retardation of thinking, speech minimizing and slow movement as classical symptom.Depression is seriously stranded
Disturbing the live and work of patient, bring white elephant to family and society, the patients with depression of about 15% dies from suicide.The world
One joint study of health organization, the World Bank and Harvard University shows, depression has become as the of China's Disease Spectrum
Two big diseases.Therefore, anti-depression drug has wide market prospect.
Paroxetine hydrochloride is a kind of high selective serotonin reuptake inhibitor, by stoping inhaling again of 5-hydroxy tryptamine
Receive and improve the concentration of 5-hydroxy tryptamine in nerve synapse gap, strengthen maincenter 5-hydroxy tryptamine function of nervous system, thus produce antidepressant
Effect.
At present, the preparation that paroxetine hydrochloride lists at home is mainly conventional tablet, there is no oral administration mixed suspension listing.Salt
Acid paroxetine tablet disintegration time is long, is difficult to absorb, and vivo biodistribution availability is low, have impact on paroxetine hydrochloride clinical treatment
The performance of effect.And, for gerontal patient or the child of a lot of dysphagias, conventional tablet takes inconvenience, and compliance is relatively
Difference；It is therefore desirable to develop a kind of applicable gerontal patient and children taking, good mouthfeel and the dosage form of taking convenience.
The present invention uses cationic resin to prepare drug-resin complex, and by the preparation technology of similar " elutriation ",
It is prepared for a kind of good mouthfeel, the paroxetine hydrochloride oral administration mixed suspension of taking convenience.Oral administration mixed suspension is ground by colloid mill
After, sedimentation stability is good, and dispersibility is preferable again, compared with conventional pharmaceutical dosage forms, oral administration mixed suspension have absorption rapidly, rise
Effect is fast, good mouthfeel, bioavailability advantages of higher, is especially suitable for child and gerontal patient takes, improve complying with of patient
Property.
Summary of the invention
It is an object of the invention to provide the novel form paroxetine hydrochloride oral mixed suspension of a kind of paroxetine hydrochloride
Liquid.It is a further object to provide the preparation method of paroxetine hydrochloride oral administration mixed suspension.
Paroxetine hydrochloride oral administration mixed suspension prescription of the present invention consists of:
Paroxetine hydrochloride 2.28 weight portion
Stabilizer 2.28-6.84 weight portion
Diluent 40-50 weight portion
Dispersant 40-60 weight portion
Wetting agent 40-60 weight portion
Acidic ph modifier 1-3 weight portion
Alkaline pH adjusting agent 1-2 weight portion
Preservative 2-4 weight portion
Correctives 400-410 weight portion
Coloring agent 0.1-0.2 weight portion
Defoamer 4-6 weight portion
Purified Water q. s
Paroxetine hydrochloride oral administration mixed suspension prescription of the present invention composition is preferably:
Paroxetine hydrochloride 2.28 weight portion
Stabilizer 4.56 weight portion
Diluent 45 weight portion
Dispersant 50 weight portion
Wetting agent 50 weight portion
Acidic ph modifier 2.0 weight portion
Alkaline pH adjusting agent 1.5 weight portion
Preservative 3 weight portion
Correctives 405 weight portion
Coloring agent 0.15 weight portion
Defoamer 5 weight portion
Purified Water q. s
Wherein stabilizer is Amberlite IRP-88, and Amberlite IRP-64 and Amberlite IRP-69 is therein
One or more mixture；Diluent is one or both mixture in microcrystalline Cellulose or sodium carboxymethyl cellulose；
Dispersant is propylene glycol；Wetting agent is glycerol；Acidic ph modifier is anhydrous citric acid；Alkaline pH adjusting agent is two citric acid monohydrates
Sodium；Preservative is in methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate or sodium benzoate
Plant or two kinds of mixture；In correctives, sweeting agent is Sorbitol, saccharin sodium, Flos Chrysanthemi essence, mannitol, fructose, sucrose, Fructus Hordei Germinatus
Sugar, lactose, glucose, xylitol, acesulfame potassium one or more mixture therein, in correctives, aromatic is that fragrant citrus is fragrant
Essence, cherry essence, peach flavor, strawberry essence, Mint Essence, Hami melon essence, Fructus Citri Limoniae essence, preferably fragrant citrus essence, lemon
Lemon essence；Coloring agent is sunset yellow, beet red pigment, carmine pigment one or more mixture therein, excellent
Select sunset yellow；Defoamer is one or both mixture during simethicone or simethicone dissipate.
The preparation method of paroxetine hydrochloride oral administration mixed suspension of the present invention is: be dissolved in dispersant by paroxetine hydrochloride,
Be slowly added in stabiliser solution, stirring make its fully react preparation resin salt complex carry out taste masking, obtain solution 1；
By wetting agent, preservative, acidic ph modifier, alkaline pH adjusting agent, correctives, diluent, coloring agent, defoamer in suitable quantity of water
Middle mix homogeneously, obtains solution 2；Solution 1 is mixed with solution 2, uses stirring or colloid mill to grind, mix homogeneously, add with pure
Change water and be settled to scale, obtain paroxetine hydrochloride oral administration mixed suspension.
The preparation method of paroxetine hydrochloride oral administration mixed suspension of the present invention is: paroxetine hydrochloride is dissolved in propylene glycol, will
It is slowly added in Amberlite IRP-88 solution, and stirring 4h makes its abundant inclusion, obtains solution 1；By glycerol, benzoic acid
Sodium, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, sunset yellow, fragrant citrus essence, simethicone are mixed in suitable quantity of water
Close uniformly, obtain solution 2；Solution 1 is mixed with solution 2, uses colloid mill to grind, make mix homogeneously, it is settled to carve by purified water
Degree, obtains paroxetine hydrochloride oral administration mixed suspension.
Formulation and technology is:
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-88 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, sunset yellow, orange essence, two
First silicone oil mix homogeneously in suitable quantity of water, obtains solution 2；
3) solution 1 is mixed with solution 2, use colloid mill to grind 10min, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
The present invention uses cation exchange resin to prepare resin salt complex to carry out taste masking and grinding technique.The hydrochloric acid prepared
Paroxetine oral administration mixed suspension, stable in properties, taking convenience, good mouthfeel.Below by way of specific embodiment, the present invention is entered
Row further illustrates.These embodiments are merely illustrative, and are not construed as limitation of the present invention.
Detailed description of the invention
Embodiment 1: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-88 4.56 g
Microcrystalline Cellulose 45 g
Propylene glycol 50 g
Glycerol 50 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Sodium benzoate 3.0 g
Sorbitol (70%w/w) 404 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-88 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, sunset yellow, fragrant citrus essence,
Simethicone is mix homogeneously in suitable quantity of water, obtains solution 2；
3) solution 1 is mixed with solution 2, use magnetic agitation 60min, make mix homogeneously, be settled to scale by purified water, obtain salt
Acid paroxetine oral administration mixed suspension.
Embodiment 2: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-88 4.56 g
Microcrystalline Cellulose 45 g
Propylene glycol 50 g
Glycerol 50 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Sodium benzoate 3.0 g
Sorbitol (70%w/w) 404 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-88 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, sunset yellow, fragrant citrus essence,
Simethicone is mix homogeneously in suitable quantity of water, obtains solution 2；
3) solution 1 is mixed with solution 2, use high-shear homogenizer homogenizing 45min, make mix homogeneously, be settled to carve by purified water
Degree, obtains paroxetine hydrochloride oral administration mixed suspension.
Embodiment 3: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-88 4.56 g
Microcrystalline Cellulose 45 g
Propylene glycol 50 g
Glycerol 50 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Sodium benzoate 3.0 g
Sorbitol (70%w/w) 404 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-88 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, sunset yellow, fragrant citrus essence,
Simethicone is mix homogeneously in suitable quantity of water, obtains solution 2；
3) solution 1 is mixed with solution 2, use colloid mill to grind 30min, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
Embodiment 4: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-69 4.56 g
Microcrystalline Cellulose 40 g
Carboxymethyl starch sodium 10 g
Propylene glycol 50 g
Glycerol 50 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Sodium benzoate 3.0 g
Sorbitol (70%w/w) 404 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-69 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, carboxymethyl starch sodium, sunset yellow
Element, fragrant citrus essence, simethicone mix homogeneously in suitable quantity of water, obtain solution 2；
3) solution 1 is mixed with solution 2, use colloid mill to grind 30min, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
Embodiment 5: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-69 4.56 g
Microcrystalline Cellulose 40 g
Carboxymethyl starch sodium 10 g
Propylene glycol 40 g
Glycerol 40 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Sodium benzoate 3.0 g
Sorbitol (70%w/w) 404 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-69 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, sodium benzoate, citric acid, sodium citrate, sorbitol, microcrystalline Cellulose, carboxymethyl starch sodium, sunset yellow
Element, fragrant citrus essence, simethicone mix homogeneously in suitable quantity of water, obtain solution 2；
3) solution 1 is mixed with solution 2, use colloid mill to grind 30min, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
Embodiment 6: paroxetine hydrochloride oral administration mixed suspension
The prescription of 1ml hydrochloric paroxetine 2.28mg, 1000ml paroxetine hydrochloride oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 g
Amberlite IRP-69 4.56 g
Microcrystalline Cellulose 40 g
Carboxymethyl starch sodium 10 g
Propylene glycol 40 g
Glycerol 40 g
Citric acid 2.0 g
Sodium citrate 1.5 g
Methyl parahydroxybenzoate 2.0 g
Propyl p-hydroxybenzoate 1.0 g
Sorbitol (70%w/w) 400 g
Sunset yellow 0.15 g
Fragrant citrus essence 1.0g
Simethicone 5 g
Purified water is settled to 1000ml
1) paroxetine hydrochloride being dissolved in propylene glycol, be slowly added in Amberlite IRP-69 solution, stirring 4h makes
It fully reacts, and obtains solution 1；
2) by glycerol, methyl parahydroxybenzoate, propyl p-hydroxybenzoate, citric acid, sodium citrate, sorbitol, crystallite fibre
Dimension element, carboxymethyl starch sodium, sunset yellow, fragrant citrus essence, simethicone mix homogeneously in suitable quantity of water, obtain solution 2；
3) solution 1 is mixed with solution 2, use colloid mill to grind 30min, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
The mouthfeel of the paroxetine hydrochloride oral administration mixed suspension of different process and prescription, sedimentation situation and redispersion Nature comparison
Result:
Paroxetine hydrochloride oral administration mixed suspension mouthfeel, sedimentation situation and redispersion character comparative result
。
Claims (10)
1. a paroxetine hydrochloride oral administration mixed suspension, it is characterised in that the prescription of this oral administration mixed suspension consists of:
Paroxetine hydrochloride 2.28 weight portion
Stabilizer 2.28-6.84 weight portion
Diluent 40-50 weight portion
Dispersant 40-60 weight portion
Wetting agent 40-60 weight portion
Acidic ph modifier 1-3 weight portion
Alkaline pH adjusting agent 1-2 weight portion
Preservative 2-4 weight portion
Correctives 400-410 weight portion
Coloring agent 0.1-0.2 weight portion
Defoamer 4-6 weight portion
Purified Water q. s.
2. paroxetine hydrochloride oral administration mixed suspension as claimed in claim 1, it is characterised in that the prescription group of this oral administration mixed suspension
Become:
Paroxetine hydrochloride 2.28 weight portion
Stabilizer 4.56 weight portion
Diluent 45 weight portion
Dispersant 50 weight portion
Wetting agent 50 weight portion
Acidic ph modifier 2.0 weight portion
Alkaline pH adjusting agent 1.5 weight portion
Preservative 3 weight portion
Correctives 405 weight portion
Coloring agent 0.15 weight portion
Defoamer 5 weight portion
Purified Water q. s.
3. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, it is characterised in that: by paroxetine hydrochloride
Make resin complexes and carry out taste masking, then mix with other adjuvants.
4. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described stabilizer is Amberlite
IRP-88, Amberlite IRP-64 and Amberlite IRP-69 one or more mixture therein.
5. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described diluent is microcrystalline cellulose
One or both mixture in element or sodium carboxymethyl cellulose.
6. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described dispersant is propylene glycol；Profit
Humectant is glycerol；Acidic ph modifier is anhydrous citric acid；Alkaline pH adjusting agent is two citric acid monohydrate sodium.
7. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described preservative is para hydroxybenzene
One or more mixture in methyl formate, ethylparaben, propyl p-hydroxybenzoate or sodium benzoate.
8. in the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described correctives, sweeting agent is
Sorbitol, saccharin sodium, Flos Chrysanthemi essence, mannitol, fructose, sucrose, maltose, lactose, glucose, xylitol, acesulfame potassium are wherein
One or more mixture, preferably sorbitol, saccharin sodium；In correctives, aromatic is fragrant citrus essence, cherry essence, water
Honey peach essence, strawberry essence, Mint Essence, Hami melon essence, Fructus Citri Limoniae essence, preferably fragrant citrus essence, Fructus Citri Limoniae essence.
9. the paroxetine hydrochloride oral administration mixed suspension as described in claim 1-2 is arbitrary, its described coloring agent is sunset yellow
Element, beet red pigment, carmine pigment one or more mixture therein, preferably sunset yellow, defoamer is two
First silicone oil or simethicone dissipate in one or both mixture.
10. the preparation method of paroxetine hydrochloride oral administration mixed suspension described in a claim 3, it is characterised in that the method is such as
Under:
1) being dissolved in dispersant by paroxetine hydrochloride, be slowly added in stabiliser solution, stirring 2-4h makes it abundant
Reaction, obtains solution 1；
2) wetting agent, preservative, acidic ph modifier, alkaline pH adjusting agent, correctives, diluent, coloring agent, defoamer are existed
Mix homogeneously in suitable quantity of water, obtains solution 2；
3) solution 1 is mixed with solution 2, be stirred or milled processed, make mix homogeneously, be settled to scale by purified water,
Paroxetine hydrochloride oral administration mixed suspension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610845382.7A CN106309363A (en) | 2016-09-24 | 2016-09-24 | Paroxetine hydrochloride oral suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610845382.7A CN106309363A (en) | 2016-09-24 | 2016-09-24 | Paroxetine hydrochloride oral suspension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309363A true CN106309363A (en) | 2017-01-11 |
Family
ID=57819856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610845382.7A Pending CN106309363A (en) | 2016-09-24 | 2016-09-24 | Paroxetine hydrochloride oral suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309363A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108926529A (en) * | 2017-05-25 | 2018-12-04 | 万特制药(海南)有限公司 | Paroxetine hydrochloride oral administration mixed suspension and its preparation process |
| CN113143860A (en) * | 2021-05-26 | 2021-07-23 | 江苏汉晨药业有限公司 | Procaterol hydrochloride oral solution |
| CN113209017A (en) * | 2021-06-02 | 2021-08-06 | 上海美优制药有限公司 | Paroxetine hydrochloride suspension and preparation method thereof |
| CN113350279A (en) * | 2021-06-02 | 2021-09-07 | 上海美优制药有限公司 | Paroxetine hydrochloride enteric sustained-release suspension and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140411A (en) * | 1994-02-03 | 1997-01-15 | 史密丝克莱恩比彻姆有限公司 | Oral liquid compositions contg. paroxetine resinate |
| EP1255549A1 (en) * | 2000-02-11 | 2002-11-13 | Smithkline Beecham Plc | Water dispersible formulation of paroxetine |
| CN104027306A (en) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | Paroxetine oral suspension and preparation method thereof |
-
2016
- 2016-09-24 CN CN201610845382.7A patent/CN106309363A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140411A (en) * | 1994-02-03 | 1997-01-15 | 史密丝克莱恩比彻姆有限公司 | Oral liquid compositions contg. paroxetine resinate |
| EP1255549A1 (en) * | 2000-02-11 | 2002-11-13 | Smithkline Beecham Plc | Water dispersible formulation of paroxetine |
| CN104027306A (en) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | Paroxetine oral suspension and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108926529A (en) * | 2017-05-25 | 2018-12-04 | 万特制药(海南)有限公司 | Paroxetine hydrochloride oral administration mixed suspension and its preparation process |
| CN113143860A (en) * | 2021-05-26 | 2021-07-23 | 江苏汉晨药业有限公司 | Procaterol hydrochloride oral solution |
| CN113209017A (en) * | 2021-06-02 | 2021-08-06 | 上海美优制药有限公司 | Paroxetine hydrochloride suspension and preparation method thereof |
| CN113350279A (en) * | 2021-06-02 | 2021-09-07 | 上海美优制药有限公司 | Paroxetine hydrochloride enteric sustained-release suspension and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6092629B2 (en) | Suspension prepared for use with rifaximin | |
| CN106309363A (en) | Paroxetine hydrochloride oral suspension and preparation method thereof | |
| JP2004535370A (en) | Liquid pharmaceutical composition with masked taste | |
| WO2005115353A1 (en) | Pharmaceutical suspension composition | |
| JP3631782B2 (en) | Liquid dosage form containing ursodeoxycholic acid | |
| WO2016028968A1 (en) | Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions | |
| CN102014904B (en) | Liquid formulation for deferiprone with palatable taste | |
| JP2021169504A (en) | Aprepitant oral liquid formulations | |
| JP2818220B2 (en) | Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them | |
| JP2008526736A (en) | Syrup composition containing dexibpropene as active ingredient and method for producing the same | |
| JPH04159223A (en) | Emetocathartic composition | |
| CN113209017A (en) | Paroxetine hydrochloride suspension and preparation method thereof | |
| TWI314454B (en) | An oral liquid pharmaceutical composition of leukotriene antagonists | |
| US9040089B2 (en) | Oral compositions of clindamycin | |
| EP1603550B1 (en) | Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid | |
| JP3341770B1 (en) | Jelly agent containing branched-chain amino acid | |
| JP6410814B2 (en) | Liquid pharmaceutical composition for oral administration containing fexofenadine | |
| WO2006067577A2 (en) | Stable non-dihydrate azithromycin oral suspensions | |
| JP2004175672A (en) | Oral liquid agent containing glycyrrhizinic acid | |
| CN112566625A (en) | Oral dosage chemotherapeutic drug suspensions | |
| WO2015137829A1 (en) | Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine | |
| US11931413B2 (en) | Dextromethorphan and guaifenesin syrup formulation or suspension | |
| WO2014147631A1 (en) | Formulation comprising gefitinib as oral suspension | |
| JPH04288013A (en) | Suspended syrup agent | |
| CN105327359A (en) | Drug for treating oral diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170111 |
|
| WD01 | Invention patent application deemed withdrawn after publication |